Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

Stefan Walzer, Christos Chouaid, Johanna Lister, Dmitry Gultyaev, Alain Vergnenegre, Filippo De Marinis, Jie Meng, Javier De Castro Carpeno, Ralph Crott, Martin Kleman, Charles Ngoh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line and second line) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is still a key research question which therapy sequence results in the best survival outcomes for patients with nsNSCLC. Methods: A therapy-sequencing disease model that approximates treatment outcomes in up to five lines of treatment was developed for patients with nsNSCLC. The primary source of data for progression-free survival (PFS) and time to death was published pivotal trial data. All patients were treatment-naïve and in the PFS state, received first-line treatment with either bevacizumab-based therapy or doublet chemotherapy (including the option of pemetrexed + cisplatin). Patients would then progress to a subsequent line of therapy, remain in PFS or die. In case of progression, it was assumed that each survivor would receive a subsequent line of therapy, based on EMA licensed therapies. Weibull distribution curves were fitted to the data. Results: All bevacizumab-based first-line therapy sequences analyzed achieved total PFS of around 15 months. Bevacizumab + carboplatin + paclitaxel (first line) → pemetrexed (second line) → erlotinib (third line) → docetaxel (fourth line) resulted in total mean PFS time of 15.7 months, for instance. Sequences with pemetrexed in combination with cisplatin in first line achieved total PFS times between 12.6 and 12.8 months with a slightly higher total PFS time achieved when assuming pemetrexed continuation therapy in maintenance after pemetrexed + cisplatin in first-line induction. Overall survival results followed the same trend as PFS. Conclusion: The model suggests that treatment-sequencing strategies starting with a bevacizumab-based combination in first line yield better survival outcomes than those starting with pemetrexed-based combinations, a result that is attributable to the possibility of one further line of treatment with first-line bevacizumab-based treatment sequences.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Pemetrexed
Therapeutics
Cisplatin
docetaxel
Survival
Information Storage and Retrieval
Carboplatin
Paclitaxel

Keywords

  • bevacizumab
  • lung cancer
  • simulation
  • therapy sequencing

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Medicine(all)

Cite this

Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. / Walzer, Stefan; Chouaid, Christos; Lister, Johanna; Gultyaev, Dmitry; Vergnenegre, Alain; De Marinis, Filippo; Meng, Jie; De Castro Carpeno, Javier; Crott, Ralph; Kleman, Martin; Ngoh, Charles.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 1, 01.01.2014, p. 121-128.

Research output: Contribution to journalArticle

Walzer, S, Chouaid, C, Lister, J, Gultyaev, D, Vergnenegre, A, De Marinis, F, Meng, J, De Castro Carpeno, J, Crott, R, Kleman, M & Ngoh, C 2014, 'Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy', Expert Review of Anticancer Therapy, vol. 15, no. 1, pp. 121-128. https://doi.org/10.1586/14737140.2015.961428
Walzer, Stefan ; Chouaid, Christos ; Lister, Johanna ; Gultyaev, Dmitry ; Vergnenegre, Alain ; De Marinis, Filippo ; Meng, Jie ; De Castro Carpeno, Javier ; Crott, Ralph ; Kleman, Martin ; Ngoh, Charles. / Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. In: Expert Review of Anticancer Therapy. 2014 ; Vol. 15, No. 1. pp. 121-128.
@article{6512ab8e0f39485f9783e9a0b3453b3e,
title = "Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy",
abstract = "Objectives: In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line and second line) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is still a key research question which therapy sequence results in the best survival outcomes for patients with nsNSCLC. Methods: A therapy-sequencing disease model that approximates treatment outcomes in up to five lines of treatment was developed for patients with nsNSCLC. The primary source of data for progression-free survival (PFS) and time to death was published pivotal trial data. All patients were treatment-na{\"i}ve and in the PFS state, received first-line treatment with either bevacizumab-based therapy or doublet chemotherapy (including the option of pemetrexed + cisplatin). Patients would then progress to a subsequent line of therapy, remain in PFS or die. In case of progression, it was assumed that each survivor would receive a subsequent line of therapy, based on EMA licensed therapies. Weibull distribution curves were fitted to the data. Results: All bevacizumab-based first-line therapy sequences analyzed achieved total PFS of around 15 months. Bevacizumab + carboplatin + paclitaxel (first line) → pemetrexed (second line) → erlotinib (third line) → docetaxel (fourth line) resulted in total mean PFS time of 15.7 months, for instance. Sequences with pemetrexed in combination with cisplatin in first line achieved total PFS times between 12.6 and 12.8 months with a slightly higher total PFS time achieved when assuming pemetrexed continuation therapy in maintenance after pemetrexed + cisplatin in first-line induction. Overall survival results followed the same trend as PFS. Conclusion: The model suggests that treatment-sequencing strategies starting with a bevacizumab-based combination in first line yield better survival outcomes than those starting with pemetrexed-based combinations, a result that is attributable to the possibility of one further line of treatment with first-line bevacizumab-based treatment sequences.",
keywords = "bevacizumab, lung cancer, simulation, therapy sequencing",
author = "Stefan Walzer and Christos Chouaid and Johanna Lister and Dmitry Gultyaev and Alain Vergnenegre and {De Marinis}, Filippo and Jie Meng and {De Castro Carpeno}, Javier and Ralph Crott and Martin Kleman and Charles Ngoh",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/14737140.2015.961428",
language = "English",
volume = "15",
pages = "121--128",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

AU - Walzer, Stefan

AU - Chouaid, Christos

AU - Lister, Johanna

AU - Gultyaev, Dmitry

AU - Vergnenegre, Alain

AU - De Marinis, Filippo

AU - Meng, Jie

AU - De Castro Carpeno, Javier

AU - Crott, Ralph

AU - Kleman, Martin

AU - Ngoh, Charles

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line and second line) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is still a key research question which therapy sequence results in the best survival outcomes for patients with nsNSCLC. Methods: A therapy-sequencing disease model that approximates treatment outcomes in up to five lines of treatment was developed for patients with nsNSCLC. The primary source of data for progression-free survival (PFS) and time to death was published pivotal trial data. All patients were treatment-naïve and in the PFS state, received first-line treatment with either bevacizumab-based therapy or doublet chemotherapy (including the option of pemetrexed + cisplatin). Patients would then progress to a subsequent line of therapy, remain in PFS or die. In case of progression, it was assumed that each survivor would receive a subsequent line of therapy, based on EMA licensed therapies. Weibull distribution curves were fitted to the data. Results: All bevacizumab-based first-line therapy sequences analyzed achieved total PFS of around 15 months. Bevacizumab + carboplatin + paclitaxel (first line) → pemetrexed (second line) → erlotinib (third line) → docetaxel (fourth line) resulted in total mean PFS time of 15.7 months, for instance. Sequences with pemetrexed in combination with cisplatin in first line achieved total PFS times between 12.6 and 12.8 months with a slightly higher total PFS time achieved when assuming pemetrexed continuation therapy in maintenance after pemetrexed + cisplatin in first-line induction. Overall survival results followed the same trend as PFS. Conclusion: The model suggests that treatment-sequencing strategies starting with a bevacizumab-based combination in first line yield better survival outcomes than those starting with pemetrexed-based combinations, a result that is attributable to the possibility of one further line of treatment with first-line bevacizumab-based treatment sequences.

AB - Objectives: In recent years, the treatment landscape in advanced non-squamous non-small-cell lung cancer (nsNSCLC) has changed. New therapies (e.g., bevacizumab indicated in first line) have become available and other therapies (e.g., pemetrexed in first line and second line) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is still a key research question which therapy sequence results in the best survival outcomes for patients with nsNSCLC. Methods: A therapy-sequencing disease model that approximates treatment outcomes in up to five lines of treatment was developed for patients with nsNSCLC. The primary source of data for progression-free survival (PFS) and time to death was published pivotal trial data. All patients were treatment-naïve and in the PFS state, received first-line treatment with either bevacizumab-based therapy or doublet chemotherapy (including the option of pemetrexed + cisplatin). Patients would then progress to a subsequent line of therapy, remain in PFS or die. In case of progression, it was assumed that each survivor would receive a subsequent line of therapy, based on EMA licensed therapies. Weibull distribution curves were fitted to the data. Results: All bevacizumab-based first-line therapy sequences analyzed achieved total PFS of around 15 months. Bevacizumab + carboplatin + paclitaxel (first line) → pemetrexed (second line) → erlotinib (third line) → docetaxel (fourth line) resulted in total mean PFS time of 15.7 months, for instance. Sequences with pemetrexed in combination with cisplatin in first line achieved total PFS times between 12.6 and 12.8 months with a slightly higher total PFS time achieved when assuming pemetrexed continuation therapy in maintenance after pemetrexed + cisplatin in first-line induction. Overall survival results followed the same trend as PFS. Conclusion: The model suggests that treatment-sequencing strategies starting with a bevacizumab-based combination in first line yield better survival outcomes than those starting with pemetrexed-based combinations, a result that is attributable to the possibility of one further line of treatment with first-line bevacizumab-based treatment sequences.

KW - bevacizumab

KW - lung cancer

KW - simulation

KW - therapy sequencing

UR - http://www.scopus.com/inward/record.url?scp=84919818822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919818822&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.961428

DO - 10.1586/14737140.2015.961428

M3 - Article

VL - 15

SP - 121

EP - 128

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 1

ER -